Aktis Oncology, Inc. (AKTS)
18.15
+0.41
(+2.31%)
USD |
NASDAQ |
Oct 09, 16:00
18.14
-0.02
(-0.08%)
After-Hours: 20:00
Aktis Oncology Shareholders Equity (Quarterly) : 484.84M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 484.84M |
| March 31, 2026 | 506.11M |
| December 31, 2025 | 187.26M |
| Date | Value |
|---|---|
| June 30, 2025 | |
| March 31, 2025 | |
| December 31, 2024 | 245.61M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 557.60M |
| Total Liabilities (Quarterly) | 72.76M |
| Debt to Equity Ratio | 0.0232 |
| Current Ratio | 16.33 |
| Net Debt Paydown Yield | 0.01% |